Canada markets open in 3 hours 50 minutes
  • S&P/TSX

    19,107.77
    -166.27 (-0.86%)
     
  • S&P 500

    4,063.04
    -89.06 (-2.14%)
     
  • DOW

    33,587.66
    -681.50 (-1.99%)
     
  • CAD/USD

    0.8245
    +0.0000 (+0.00%)
     
  • CRUDE OIL

    64.57
    -1.51 (-2.29%)
     
  • BTC-CAD

    60,428.89
    -8,981.23 (-12.94%)
     
  • CMC Crypto 200

    1,344.88
    -218.95 (-14.00%)
     
  • GOLD FUTURES

    1,814.40
    -8.40 (-0.46%)
     
  • RUSSELL 2000

    2,135.14
    -71.85 (-3.26%)
     
  • 10-Yr Bond

    1.6950
    0.0000 (0.00%)
     
  • NASDAQ futures

    12,977.00
    -21.50 (-0.17%)
     
  • VOLATILITY

    27.56
    +5.72 (+26.19%)
     
  • FTSE

    6,860.30
    -144.33 (-2.06%)
     
  • NIKKEI 225

    27,448.01
    -699.50 (-2.49%)
     
  • CAD/EUR

    0.6828
    +0.0004 (+0.06%)
     

Global Inhaled Nitric Oxide Market (2020 to 2026) - by Application and Region - ResearchAndMarkets.com

·3 min read

The "Global Inhaled Nitric Oxide Market By Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS) and Other Applications), By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.

The global inhaled nitric oxide market size is expected to reach $915.7 Million by 2026, rising at a market growth of 7% CAGR during the forecast period.

Nitric oxide is a molecule of gas that causes a sense of relaxation in smooth muscle cells in the vasculature. It is because Nitric Oxide reacts with oxyhemoglobin. The gas is quickly collected by oxyhemoglobin in red blood cells and the vasodilating effects caused by inhaled nitric oxide are restricted to oxygenated areas of the lungs. Thus, this distinct ability of Nitric oxide to cause pulmonary vasodilatation in the oxygenated regions of the lung helps in enhancing oxygenation of the blood and reduces intrapulmonary right to left shunting. Hence, the inhaled nitric oxide is utilized to cure various cardiopulmonary conditions, like pulmonary hypertension in adults and children. Although, the usage of inhaled nitric oxide is restricted due to logistical and financial reasons.

The rising prevalence of diseases in infants like a neonatal hypoxic respiratory failure (HRF) and persistent pulmonary hypertension is among the key driving factors of the market. Moreover, the growing number of patients with chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS) also propel the market growth. Apart from this, the huge cost involved in the treatment & the stringent government policies on different applications of the gas are restricting the growth of Inhaled Nitric Oxide market. However, the constant R&D activities for discovering various new applications in the healthcare sector are estimated to offer profitable opportunities for expanding the global inhaled nitric oxide market during the forecast period.

The declaration of WHO about the Covid-19 outbreak as a public health emergency has affected every country around the globe. During the pandemic, nitric oxide got under several experiments to test whether it can help in treating Covid-19 affected people, due to its antiviral properties and enhanced oxygenation. Inhaled Nitric Oxide is useful in safeguarding the frontline healthcare workers from this pandemic.

Companies Profiled

  • Getinge AB

  • Merck Group

  • Halma PLC

  • Linde PLC (Praxair, Inc.)

  • Air Liquide S.A.

  • Beyond Air, Inc.

  • Mallinckrodt PLC (International Minerals and Chemical Corporation)

  • VERO Biotech LLC

  • Nu-Med Plus, Inc.

  • Novoteris, LLC

Unique Offerings from the Publisher

  • Exhaustive coverage

  • Highest number of market tables and figures

  • Subscription based model available

  • Guaranteed best price

  • Assured post sales research support with 10% customization free

Key Topics Covered:

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview

2.1 Introduction

2.1.1 Overview

2.1.2 Market composition

2.2 Key Factors Impacting the Market

2.2.1 Market Drivers

2.2.2 Market Restraints

Chapter 3. Strategies deployed in Inhaled Nitric Oxide Market

Chapter 4. Global Inhaled Nitric Oxide Market by Application

4.1 Global Neonatal Respiratory Treatment Repellent Market by Region

4.2 Global Chronic Obstructive Pulmonary Disease (COPD) Repellent Market by Region

4.3 Global Acute Respiratory Distress Syndrome (ARDS) Market by Region

4.4 Global Other Applications Market by Region

Chapter 5. Global Inhaled Nitric Oxide Market by Region

5.1 North America Inhaled Nitric Oxide Market

5.2 Europe Inhaled Nitric Oxide Market

5.3 Asia Pacific Inhaled Nitric Oxide Market

5.4 LAMEA Inhaled Nitric Oxide Market

Chapter 6. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/jz5thq

View source version on businesswire.com: https://www.businesswire.com/news/home/20210416005286/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900